ABVC BioPharma, Inc.: ABVC BioPharma Provides 2023 Pipeline

FREMONT, CA, Feb. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology

Related Keywords

Fremont , California , United States , Australia , Taiwan , Japan , Thailand , Massachusetts , Stanford University , West Hollywood , San Francisco , Dennis Riedl , Thomas Laughren , Howard Doong , Leeds Chow , University Of California , Sinai Medical Center , Clinical Trials Network , Cedars Sinai Medical Center , Nasdaq , Biopharma Inc , Exchange Commission , Company Annual Report On Form , Psychiatry Clinical Trials Network , Stanford University Medical Center , Division Of Psychiatry Products , University Of California At San Francisco , Memorial Sloan Kettering Cancer Center , Depressive Disorder , Maurizio Fava , Central Nervous System , Massachusetts General Hospital , Slater Family Professor , Harvard Medical , Division Director , Psychiatry Products , Drug Evaluation , Patient Depression , Memorial Sloan Kettering Cancer , Chief Executive Officer , For Vitargus , Annual Report , Quarterly Reports , Abvc , Iopharma , Rovides , 023 , Pipeline , Update ,